CSL Limited v GlaxoSmithKline Australia Pty Ltd [2006] FCA 1301
PRACTICE AND PROCEDURE – interlocutory injunction – quia timet injunction – whether serious question to be tried – whether applicant likely to suffer injury for which damages will not be an adequate remedy – whether balance of convenience favours the granting of injunction – alleged contravention of s 52 of Trade Practices Act 1974 (Cth)
Held: injunction refused on balance of convenience; speedy trial ordered
R Meagher, D Heydon and M Leeming, Meagher, Gummow & Lehane’s Equity Doctrines & Remedies (2002, 4th ed) Dr I C F Spry, Equitable Remedies (2001, 6th ed)
CSL LIMITED (ACN 051 588 348) v GLAXOSMITHKLINE AUSTRALIA PTY LTD (ACN 100 162 481) VID 1002 OF 2006
WEINBERG J 3 OCTOBER 2006 MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 1002 OF 2006
BETWEEN:
CSL LIMITED (ACN 051 588 348) Applicant
AND:
GLAXOSMITHKLINE AUSTRALIA PTY LTD (ACN 100 162 481) Respondent
JUDGE:
WEINBERG J
DATE OF ORDER:
3 OCTOBER 2006
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1.The application for interlocutory injunctive relief be refused.
2.The question of costs be stood over to a date to be fixed.
3.The trial fixed for 13 November 2006 be limited to questions of liability and injunctive relief. The issue of damages be listed, if necessary, for hearing on a date to be fixed.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 1002 OF 2006
BETWEEN:
CSL LIMITED (ACN 051 588 348) Applicant
AND:
GLAXOSMITHKLINE AUSTRALIA PTY LTD (ACN 100 162 481) Respondent
JUDGE:
WEINBERG J
DATE:
3 OCTOBER 2006
PLACE:
MELBOURNE
REASONS FOR JUDGMENT
The applicant, CSL Limited (“CSL”), seeks an interlocutory injunction to restrain the respondent, GlaxoSmithKline Australia Pty Ltd (“GSKA”), from making certain representations concerning GARDASIL, a vaccine marketed by CSL, and CERVARIX, a vaccine which GSKA hopes to market in Australia in the near future.
CSL carries on business developing, manufacturing, selling and supplying in Australia plasma products, antivenoms and human vaccines. GSKA markets throughout Australia a range of pharmaceutical products including vaccines.
The products at the centre of this dispute are vaccines used for the prevention of infection caused by Human Papillomavirus (“HPV”). More particularly, they are vaccines which are administered to prevent certain types of cancer.
The background facts
GARDASIL is the world’s first cervical cancer vaccine. It is, at present, the only such vaccine approved in Australia. It prevents cervical cancer and other HPV related cancers and diseases caused by HPV types 6, 11,…
Grounds of appeal
[14] The appellant contends that the primary judge erred in finding that the respondent had discharged the onus of establishing the matters required under the relevant provision.
[15] It was submitted that his Honour failed to give adequate weight to the evidence of the second witness, and that the findings of fact were not reasonably open on the material before the Court.
[16] The respondent, for its part, submits that no error is disclosed, and that the conclusions reached were well within the range of outcomes available to the primary judge.
Consideration
[17] It is convenient to deal first with the question of construction, as the resolution of that issue informs the remaining grounds advanced by the appellant.
[18] For the reasons that follow, we are of the view that the appeal should be allowed in part and the matter remitted for further determination.
Keep reading for free
Create a free CaseChat account to read CSL Limited v GlaxoSmithKline Australia Pty Ltd and more:
CSL Limited brought an action against GlaxoSmithKline Australia Pty Ltd (GSKA) seeking interlocutory injunctive relief in relation to certain representations that GSKA had made about its own HPV vaccine, CERVARIX. CSL contended that GSKA's representations were misleading or deceptive and had the potential to cause harm to CSL by damaging the reputation of its own HPV vaccine, GARDASIL, and causing loss of market share and financial loss. GSKA opposed the application on the basis that it would suffer significant prejudice and there was no real risk of harm to CSL. The case was heard by the Federal Court of Australia.
The court was required to decide whether the balance of convenience favoured the granting of interlocutory injunctive relief in favour of CSL. In considering this, the court took into account the degree of probability of the apprehended injury, the degree of the seriousness of the injury, and the requirements of justice between the parties. The court noted that there was a serious question to be tried in relation to certain of the representations made by GSKA, but it was not satisfied that the risk of harm to CSL was sufficiently high to warrant the grant of an injunction at that stage.
The court found that there was no evidence of any real irreparable harm to CSL and that GSKA's inability to make the representations complained of would place it at a significant disadvantage in the HPV vaccine market. The court also noted that GSKA had proffered undertakings and agreed to a speedy trial. Accordingly, the court refused the interlocutory injunctive relief sought by CSL. The question of costs was stood over to a later date, and the trial was fixed for 13 November 2006 to be limited to questions of liability and injunctive relief. The issue of damages was to be listed for hearing on a date to be fixed.
In summary, the court refused CSL's application for interlocutory injunctive relief against GSKA's representations about its HPV vaccine, CERVARIX. The court found that there was no real risk of harm to CSL at that stage, and that GSKA's inability to make the representations complained of would place it at a significant disadvantage in the HPV vaccine market. The court also noted that GSKA had proffered undertakings and agreed to a speedy trial. The issue of costs was stood over, and the trial was fixed for 13 November 2006.
Orders
Orders of the court
1. The application for interlocutory injunctive relief be refused.
2. The question of costs be stood over to a date to be fixed.
3. The trial fixed for 13 November 2006 be limited to questions of liability and injunctive relief. The issue of damages be listed, if necessary, for hearing on a date to be fixed.
Background
Background to the litigation
The products at the centre of this dispute are vaccines used for the prevention of infection caused by Human Papillomavirus (“HPV”). More particularly, they are vaccines which are administered to prevent certain types of cancer. The background facts GARDASIL is the world’s first cervical cancer vaccine. It is, at present, the only such vaccine approved in Australia. It prevents cervical cancer and other HPV related cancers and diseases caused by HPV types 6, 11, 16 and 18. It was developed following collaboration between CSL and Professor Ian Frazer, who is well-known for his groundbreaking research in this area, and was named Australian of the Year in 2006. The vaccine has achieved widespread recognition. In 1995, CSL granted an exclusive worldwide licence of its proprietary technology to Merck & Co., Inc. which conducted substantial research leading to the development of GARDASIL. On 14 December 2005, Merck Sharp & Dohme (Australia) Pty Ltd lodged an application with the Therapeutic Goods Authority (“the TGA”) for marketing approval for GARDASIL. On 16 June 2006, the TGA granted that approval. The TGA also granted CSL approval to use what is described as the “GARDASIL Product Information Sheet”, a document containing technical information regarding the nature and effect of the vaccine. The Product Information Sheet describes GARDASIL as a recombinant, quadrivalent vaccine:“The quadrivalent Human Papillomavirus Virus-Like Particle vaccine (HPV VLP vaccine) is a sterile liquid suspension prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16 and 18. The L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895) and self-assembled into VLPs. The VLPs for each type are purified and adsorbed on aluminum-containing adjuvant (amorphous aluminum hydroxyphosphate sulfate). The quadrivalent HPV VLP vaccine is prepared by combining the adsorbed VLPs of each HPV type, the aluminum-containing adjuvant formulation, and a buffer.GARDASIL is a sterile preparation for intramuscular administration. Each 0.5-mL dose contains approximately 20 mcg of HPV 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein.Each 0.5-mL dose of the vaccine contains approximately 225 mcg of aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, and water for injection. The product does not contain a preservative or antibiotics.” GARDASIL is “indicated” in females aged 9 to 26 years for the prevention of cervical, vulvar, and vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by HPV types 6, 11, 16 and 18 (which are included in the vaccine). It is also indicated in males aged 9 to 15 years for the prevention of infection caused by HPV types 6, 11, 16 and 18. It is administered intramuscularly in three separate doses over a period of some months, and a subsequent booster is required some years later.
Evidence
Evidence Before The Court
GSKA, in its written submissions, did not deal directly with the issue of irreparable harm. It addressed that question more generally under the ambit of balance of convenience.Balance of convenience – the evidence The evidence regarding balance of convenience comes essentially from two sources. On behalf of CSL, Dr John Anderson, its Director, Sales & Marketing of its Pharmaceuticals Division swore two affidavits dated 11 September 2006 and 18 September 2006 respectively. In an affidavit sworn on 21 September 2006, David Herd, GSKA’s Director, Regulatory Affairs and Health Outcomes & Pricing responded to Dr Anderson’s affidavits. Put simply, Dr Anderson claimed that the GSKA Information Sheet, and follow-up interviews, represented CERVARIX was superior to GARDASIL, and did so in a manner that was misleading or deceptive. He said that, based upon his experience of the conduct of genuine market research, and the numerous errors in the information distributed by GSKA, he considered that GSKA had attempted to create “fear, uncertainty and doubt” about GARDASIL in order to reduce market confidence in that product. He said that this was a well-known marketing tactic known as “FUD”. Dr Anderson observed that as GARDASIL was the only vaccine currently approved by the TGA, it was the only vaccine that the Pharmaceutical Benefits Advisory Committee (“the PBAC”) could presently assess for the proposed mass immunisation program for prevention of cervical cancer. He spoke of the potential size of the market for GARDASIL in Australia, and the maximum sales that might be realised if every eligible female and male received the full three course dosage at the full price. The figure equated to a staggering $1.2 billion. Dr Anderson noted that the PBAC was currently considering CSL’s proposal to conduct annual national vaccination of 12 year old girls, and a catch-up program for girls and women aged 13 to 26 years. He said that he was concerned that if the conduct complained of was not stopped immediately, and steps taken to correct the misinformation previously put out by GSKA, that misinformation could be conveyed to members of the PBAC and influence its decision. He said the misleading information could also influence federal cabinet to delay funding of GARDASIL until CERVARIX became available if they believed GSKA’s claims that CERVARIX might be a better vaccine. He said that he was also concerned that State and Territory decision-makers, with inadequate scientific knowledge or experience, might be influenced in relation to the assessment of tenders by the dissemination of such information. Dr Anderson said that it was highly likely that misinformation of this nature could spread rapidly within the medical community. He noted that the issue had also received substantial media coverage as a result of the GARDASIL launch activities and the high profile of Professor Frazer’s work. He said that he believed that the only way the damage being suffered by CSL could be reduced is if GSKA were immediately restrained from repeating the representations that are the subject of this proceeding.
Decision
Reasons for decision
WEINBERG J
GSKA submitted that its inability to do any of the above would severely hamper it in its preparation for the launch of CERVARIX in Australia and place it at a disadvantage to CSL in the Australian HPV vaccine market, over and above that which it already faced simply by being second to market. It submitted that CSL, by bringing this proceeding, was seeking to secure a monopoly in Australia for the supply and sale of GARDASIL to which it was not entitled by excluding GSKA from the relevant market for as long as possible. It submitted that in circumstances where it had proffered undertakings and agreed to a speedy trial and where there was no evidence of any real irreparable harm to CSL, the balance of convenience favoured the refusal of interlocutory relief.Conclusion The interlocutory relief sought by CSL is in the nature of a quia timet injunction. That is, what CSL seeks is an injunction to prevent or restrain an apprehended or threatened wrong which would result in substantial damage if committed. In quia timet proceedings, the court will have regard to the degree of probability of the apprehended injury, the degree of the seriousness of the injury, and the requirements of justice between the parties. In R v McFarlane; Ex parte O’Flannagan and O’Kelly (1923) 32 CLR 518 Isaacs J observed (at 539):“The Court is not entitled to apply the obstacle of injunction to the contemplated action of a co-ordinate branch of the Government unless not only a clear case of illegality, proved to be calculated to result in a clear injury, is established, but also it is shown that by no other means can injury be averted or sufficiently compensated for.” Dr I C F Spry, in Equitable Remedies (2001, 6th ed), comments (at 378) that quia timet injunctions are not granted unless the imminence of the act to be prohibited is sufficiently clearly established to justify the court’s intervention. The fact that there is no breach presently occurring may make it more difficult, as a matter of evidence, to establish that there is a sufficient risk of a future injury to justify the immediate grant of an injunction. If, in all the circumstances, the likelihood that an injury will take place is not sufficiently high, quia timet relief will be refused. The applicant will be left either to avail him or herself of such other remedies as may be open, or else to renew his or her application should the likelihood of an injury subsequently increase sufficiently to render equitable intervention appropriate. There is some debate as to whether a greater degree of proof is required in a case involving interlocutory quia timet relief than in a case involving a different kind of injunction. The issue is discussed in Meagher, Gummow & Lehane (at [21-395]), and need not be further canvassed here. It is sufficient to note that, in many cases, it may be more difficult to prove that an apprehended injury will occur than it is to prove that an existing injury will continue. I have already indicated that I am satisfied that there is a serious question to be tried in relation to representations 10(a), (d), (f), (g), (h), (i), (j) and (k) as pleaded in CSL’s Statement of Claim. The allegations relating to some of those representations appear to me to be stronger than those relating to others. However, nothing of any consequence turns upon this for the purposes of this interlocutory application.